Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shigehisa Kitano

Showing results (71-80 of 150) with videos related to

Pageof 15
Sort By:
Cancer Immunology, Immunotherapy : CII|March 30, 2024
Ezabenlimab (BI 754091), an anti-PD-1 antibody, in patients with advanced solid tumoursManish R Patel, Melissa Johnson, Ira Winer, et al.
Journal of Dermatological Science|July 13, 2010
Granzyme B is a novel interleukin-18 converting enzymeYouichi Omoto, Keiichi Yamanaka, Kazuya Tokime, et al.
Cancer Science|May 26, 2020
Microsatellite instability and mismatch repair protein expressions in lymphocyte-predominant breast cancerYoshiya Horimoto, May Thinzar Hlaing, Harumi Saeki, et al.
International Journal of Hematology|May 8, 2015
Infusion of donor lymphocytes expressing the herpes simplex virus thymidine kinase suicide gene for recurrent hematologic malignancies after allogeneic hematopoietic stem cell transplantationHisayoshi Hashimoto, Shigehisa Kitano, Ryosuke Ueda, et al.
Cancer Chemotherapy and Pharmacology|June 18, 2016
Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancerYutaka Fujiwara, Kenji Tamura, Shunsuke Kondo, et al.
Data in Brief|September 19, 2022
Data of programmed death-ligand 1 expression and VEGF: Nivolumab, bevacizumab and paclitaxel For HER2-negative metastatic breast cancerYukinori Ozaki, Junji Tsurutani, Toru Mukohara, et al.
Future Oncology (London, England)|January 16, 2025
Open-label, phase Ia study of STING agonist BI 1703880 plus ezabenlimab for patients with advanced solid tumorsKevin Harrington, Shigehisa Kitano, Valentina Gambardella, et al.
Japanese Journal of Clinical Oncology|February 23, 2021
The safety, tolerability and pharmacokinetics of niraparib in Japanese patients with solid tumours: results of a phase I dose-escalation studyKan Yonemori, Toshio Shimizu, Shunsuke Kondo, et al.
Cancer Chemotherapy and Pharmacology|April 8, 2021
Phase I study of tamibarotene monotherapy in pediatric and young adult patients with recurrent/refractory solid tumorsChika Nitani, Junichi Hara, Hiroshi Kawamoto, et al.
Endocrinology|February 10, 2024
Effects of the Cortisol Milieu on Tumor-Infiltrating Immune Cells in Corticotroph TumorsMaki Kanzawa, Hiroki Shichi, Keitaro Kanie, et al.
Pageof 15

Showing results (71-80 of 150) with videos related to

Sort By:
Pageof 15
Cancer Immunology, Immunotherapy : CII|March 30, 2024
Ezabenlimab (BI 754091), an anti-PD-1 antibody, in patients with advanced solid tumoursManish R Patel, Melissa Johnson, Ira Winer, et al.
Journal of Dermatological Science|July 13, 2010
Granzyme B is a novel interleukin-18 converting enzymeYouichi Omoto, Keiichi Yamanaka, Kazuya Tokime, et al.
Cancer Science|May 26, 2020
Microsatellite instability and mismatch repair protein expressions in lymphocyte-predominant breast cancerYoshiya Horimoto, May Thinzar Hlaing, Harumi Saeki, et al.
International Journal of Hematology|May 8, 2015
Infusion of donor lymphocytes expressing the herpes simplex virus thymidine kinase suicide gene for recurrent hematologic malignancies after allogeneic hematopoietic stem cell transplantationHisayoshi Hashimoto, Shigehisa Kitano, Ryosuke Ueda, et al.
Cancer Chemotherapy and Pharmacology|June 18, 2016
Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancerYutaka Fujiwara, Kenji Tamura, Shunsuke Kondo, et al.
Data in Brief|September 19, 2022
Data of programmed death-ligand 1 expression and VEGF: Nivolumab, bevacizumab and paclitaxel For HER2-negative metastatic breast cancerYukinori Ozaki, Junji Tsurutani, Toru Mukohara, et al.
Future Oncology (London, England)|January 16, 2025
Open-label, phase Ia study of STING agonist BI 1703880 plus ezabenlimab for patients with advanced solid tumorsKevin Harrington, Shigehisa Kitano, Valentina Gambardella, et al.
Japanese Journal of Clinical Oncology|February 23, 2021
The safety, tolerability and pharmacokinetics of niraparib in Japanese patients with solid tumours: results of a phase I dose-escalation studyKan Yonemori, Toshio Shimizu, Shunsuke Kondo, et al.
Cancer Chemotherapy and Pharmacology|April 8, 2021
Phase I study of tamibarotene monotherapy in pediatric and young adult patients with recurrent/refractory solid tumorsChika Nitani, Junichi Hara, Hiroshi Kawamoto, et al.
Endocrinology|February 10, 2024
Effects of the Cortisol Milieu on Tumor-Infiltrating Immune Cells in Corticotroph TumorsMaki Kanzawa, Hiroki Shichi, Keitaro Kanie, et al.
Pageof 15